BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29580612)

  • 1. Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.
    Élie V; Leroux S; Kaguelidou F; Jacqz-Aigrain E
    Therapie; 2018 Apr; 73(2):113-117. PubMed ID: 29580612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
    Ceci A; Felisi M; Baiardi P; Bonifazi F; Catapano M; Giaquinto C; Nicolosi A; Sturkenboom M; Neubert A; Wong I
    Eur J Clin Pharmacol; 2006 Nov; 62(11):947-52. PubMed ID: 17021892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K; Senn S
    Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More medicines for children: impact of the EU paediatric regulation.
    Nordenmalm S; Tomasi P; Pallidis C
    Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans.
    Wimmer S; Rascher W; McCarthy S; Neubert A
    Paediatr Drugs; 2014 Oct; 16(5):397-406. PubMed ID: 25056717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NIHR Medicines for Children Research Network: improving children's health through clinical research.
    Rose AC; Van't Hoff W; Beresford MW; Tansey SP
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):581-7. PubMed ID: 24070097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress review of the European Paediatric Regulatory Framework after six years of implementation.
    Mentzer D
    Int J Pharm; 2014 Aug; 469(2):240-3. PubMed ID: 24613178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who are the PDCO?
    Dempsey EM; Connolly K
    Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric drug regulation: International perspectives.
    Baum VC; Bax R; Heon D; Yang Z; Sakiyama M
    Paediatr Anaesth; 2019 Jun; 29(6):572-582. PubMed ID: 30924233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory policies on medicines for psychiatric disorders: is Europe on target?
    Barbui C; Garattini S
    Br J Psychiatry; 2007 Feb; 190():91-3. PubMed ID: 17267922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence.
    Ceci A; Giaquinto C; Aboulker JP; Baiardi P; Bonifazi F; Della Pasqua O; Nicolosi A; Taruscio D; Sturkenboom M; Wong I
    Paediatr Drugs; 2009; 11(1):18-21. PubMed ID: 19127946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.
    Tsukamoto K; Carroll KA; Onishi T; Matsumaru N; Brasseur D; Nakamura H
    Clin Ther; 2016 Mar; 38(3):574-81. PubMed ID: 26869192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.